MODIFICATION
68 -- Pediatric Formulation (Liquid) Potassium Iodide (KI)
- Notice Date
- 12/20/2004
- Notice Type
- Modification
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, Office of the Secretary, Office of Public Health Emergency Preparedness, Office of Research and Development Coordination 200 Independence Avenue, SW Room 636G, Washington, DC, 20201
- ZIP Code
- 20201
- Solicitation Number
- DHHS-ORDC-05-01
- Response Due
- 1/3/2005
- Point of Contact
- Rebecca Guenthner, Contracting officer, Phone 301-496-3876, Fax 301-480-3695,
- E-Mail Address
-
rg45t@nih.gov
- Description
- This is a Notice of Intent to negotiate on a Sole Source basis. The U.S. Government has an urgent need to acquire and maintain within the Strategic National Stockpile (SNS) a Pediatric Formulation of Potassium Iodide for children under the age of 10 years who live within a 20 mile radius of commercial nuclear power reactors that are included in the States with Potassium Iodide Distribution Programs. Iodine is an essential component of thyroid hormones. Thyroid hormones are also essential to life having influence on development, growth, and metabolism. If radioactive iodine (radioiodine) enters the body, it will concentrate in the thyroid gland. Radioiodine exposure to the thyroid gland can lead to thyroid cancer or, if the radioactivity dose is large enough, destroy the thyroid gland. The population at highest risk for radioiodine exposure is children, due to the fact that children require thyroid hormone for normal growth and development. Following a nuclear detonation or reactor accident, several radioactive isotopes, including radioiodine, would be dispersed into the environment. One strategy developed to prevent incorporation of radioiodine into the thyroid gland is to saturate the thyroid gland with non-radioactive "stable" iodine so that if the thyroid is exposed to radioiodine, it will not take up radioiodine. The Government intends to enter into a sole source contract with the only currently known manufacturer of Potassium Iodide in a liquid formulation, Fleming and Company Pharmaceuticals of Fenton, Missouri. A commercial item award, resulting from a written RFP, with a base year and four option years is anticipated. The anticipated award date is on or about March 1, 2005. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this requirement by submitting a capabilities statement to Terrie Nestor at the e-mail address below by January 3, 2005. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Comments to this announcement, referencing synopsis DHHS-ORDC-05-01 may be submitted to Terrie Nestor at (301) 402-6790 or in writing to tnestor@niaid.nih.gov. NOTE: THIS NOTICE MAY HAVE POSTED ON WWW.FEDBIZOPPS.GOV ON THE DATE INDICATED IN THE NOTICE ITSELF (20-DEC-2004). IT ACTUALLY APPEARED OR REAPPEARED ON THE FEDBIZOPPS SYSTEM ON 21-MAR-2005, BUT REAPPEARED IN THE FTP FEED FOR THIS POSTING DATE. PLEASE CONTACT fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/OOS/OASPHEP/DHHS-ORDC-05-01/listing.html)
- Place of Performance
- Address: Fenton, MO
- Zip Code: 63026
- Zip Code: 63026
- Record
- SN00772903-F 20050323/050321212736 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |